Giaginis Costas, Tsourouflis Gerasimos, Theocharis Stamatios
Department of Forensic Medicine and Toxicology, Medical School, University of Athens, Athens 11527, Greece.
Curr Mol Med. 2008 Sep;8(6):562-79. doi: 10.2174/156652408785748022.
Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands constitute important insulin sensitizers that have already been used for the treatment of human metabolic disorders, exerting also pleiotropic effects on inflammatory related diseases and cancer. Ischemia-reperfusion injury that is mainly associated with organ transplantation constitutes a serious complication with a great relevance in clinical practice. Accumulating experimental data have recently revealed that natural and synthetic PPAR-gamma ligands exert beneficial effects against ischemia-reperfusion injury. The present review summarizes the available information on the role of PPAR-gamma ligands in ischemia-reperfusion injury amongst the different organ systems. Taking into consideration the data so far, PPAR-gamma ligands seem to represent potential therapeutic agents in the aim to reduce or even prevent injury associated with ischemia-reperfusion.
过氧化物酶体增殖物激活受体γ(PPAR-γ)配体是重要的胰岛素增敏剂,已被用于治疗人类代谢紊乱,对炎症相关疾病和癌症也具有多效性作用。主要与器官移植相关的缺血再灌注损伤是临床实践中一种严重且极为相关的并发症。最近,越来越多的实验数据表明,天然和合成的PPAR-γ配体对缺血再灌注损伤具有有益作用。本综述总结了不同器官系统中PPAR-γ配体在缺血再灌注损伤中的作用的现有信息。考虑到目前的数据,PPAR-γ配体似乎是减少甚至预防与缺血再灌注相关损伤的潜在治疗药物。